Compare OSBC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | DRTS |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 978.2M |
| IPO Year | 2014 | N/A |
| Metric | OSBC | DRTS |
|---|---|---|
| Price | $22.25 | $9.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $23.50 | $8.67 |
| AVG Volume (30 Days) | 285.4K | ★ 1.0M |
| Earning Date | 04-22-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.20 | N/A |
| Revenue Next Year | $3.66 | $699.98 |
| P/E Ratio | $46.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.43 | $2.87 |
| 52 Week High | $22.43 | $11.62 |
| Indicator | OSBC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 52.11 |
| Support Level | $19.21 | $6.59 |
| Resistance Level | $22.43 | $11.48 |
| Average True Range (ATR) | 0.51 | 0.95 |
| MACD | 0.11 | -0.18 |
| Stochastic Oscillator | 90.17 | 39.15 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.